Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study.

JTO Clin Res Rep · 2025 · PMC12476069 · PMID 41018053

Europe PMC DOI

hedged sentence

0.1818

closest p · 3.6× alpha

0.1818

boldest claim

The sentences

a nonsignificant trendp = 0.1818not close (p > 0.1)

There was also a nonsignificant trend for fewer median co-mutations in the LC compared with the SC group (1 versus 2, respectively, p = 0.1818).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.